Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: (R,S)-Atenolol is a beta 1-adrenergic receptor antagonist with Ki values of 1.14 and 48.7 µM for beta 1 and beta 2, respectively. It has been reported that only the (S) enantiomer contributes to the beta-blocking effects of racemic atenolol. Beta-blockers, including atenolol, have diverse applications in cardiology and vascular disease.
(R,S)-Atenolol is supplied as a crystalline solid. A stock solution may be made by dissolving the (R,S)-atenolol in the solvent of choice. (R,S)-Atenolol is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of (R,S)-atenolol in these solvents is approximately 5, 15, and 20 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of (R,S)-atenolol can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of (R,S)-atenolol in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.
Golf, S., Bjurnerheim, R., Erichsen, A., et al. Relative selectivity of different β-adrenoceptor antagonists for human heart β1- and β2-receptor subtypes assayed by a radioligand binding technique. Scand. J. Clin. Lab. Invest. 47(7), 719-723 (1987).
Stoschitzky, K., Egginger, G., Zernig, G., et al. Stereoselective features of (R)- and (S)-atenolol: Clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality 5(1), 15-9 (1993).
Mehvar, R. and Brocks, D.R. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J. Pharm. Pharm. Sci. 4(2), 185-200 (2001).
Baker, J.G. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br. J. Pharmacol. 144(3), 317-322 (2005).